Federalisation of the European Union

BREAKTHROUGH PRIZE OPENS PUBLIC NOMINATIONS FOR 2024 PRIZES IN FUNDAMENTAL PHYSICS, LIFE SCIENCES & MATHEMATICS

Retrieved on: 
Jeudi, janvier 19, 2023
Tao, Maxim Kontsevich, Breakthrough Prize in Life Sciences, ALLEA, Physics, Parkinson's disease, New Horizons, Titia de Lange, Committee, Kavli Institute for the Physics and Mathematics of the Universe, Social, Breakthrough Prize in Mathematics, Neurodegeneration, Breakthrough Prize, Knowledge, ResearchGate, Woman, Doctor of Philosophy, Research, SAN, Science and Technology Select Committee, Breakthrough Prize in Fundamental Physics, Life, Federalisation of the European Union, Selection Committee, Interaction, Pharmaceutical industry, Interior design, Mathematics, Science, Humanities

SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- The public nomination period for the 2024 Breakthrough Prizes in Fundamental Physics, Life Sciences and Mathematics is now open.

Key Points: 
  • SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- The public nomination period for the 2024 Breakthrough Prizes in Fundamental Physics, Life Sciences and Mathematics is now open.
  • For the 12th year, the Breakthrough Prize, recognized as the world's largest science prize, will honor top scientists, handing out three prizes in Life Sciences, one in Fundamental Physics and one in Mathematics.
  • ResearchGate members are encouraged to nominate their peers for the 2024 prizes in Fundamental Physics, Life Sciences, and Mathematics.
  • One 2024 Breakthrough Prize in Mathematics ($3 million) will be awarded to an individual who has made outstanding contributions to the field of mathematics.

BREAKTHROUGH PRIZE OPENS PUBLIC NOMINATIONS FOR 2024 PRIZES IN FUNDAMENTAL PHYSICS, LIFE SCIENCES & MATHEMATICS

Retrieved on: 
Jeudi, janvier 19, 2023
Tao, Maxim Kontsevich, Breakthrough Prize in Life Sciences, ALLEA, Physics, Parkinson's disease, New Horizons, Titia de Lange, Committee, Kavli Institute for the Physics and Mathematics of the Universe, Social, Breakthrough Prize in Mathematics, Neurodegeneration, Breakthrough Prize, Knowledge, ResearchGate, Woman, Doctor of Philosophy, Research, SAN, Science and Technology Select Committee, Breakthrough Prize in Fundamental Physics, Life, Federalisation of the European Union, Selection Committee, Interaction, Pharmaceutical industry, Interior design, Mathematics, Science, Humanities

SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- The public nomination period for the 2024 Breakthrough Prizes in Fundamental Physics, Life Sciences and Mathematics is now open.

Key Points: 
  • SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- The public nomination period for the 2024 Breakthrough Prizes in Fundamental Physics, Life Sciences and Mathematics is now open.
  • For the 12th year, the Breakthrough Prize, recognized as the world's largest science prize, will honor top scientists, handing out three prizes in Life Sciences, one in Fundamental Physics and one in Mathematics.
  • ResearchGate members are encouraged to nominate their peers for the 2024 prizes in Fundamental Physics, Life Sciences, and Mathematics.
  • One 2024 Breakthrough Prize in Mathematics ($3 million) will be awarded to an individual who has made outstanding contributions to the field of mathematics.

Microcrystalline Cellulose Global Market Report 2022: Increasing Demand from Pharmaceutical Industry Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Mercredi, janvier 18, 2023
Chemicals, Plastics, Natural Resources, Other Natural Resources, Manufacturing, European Federation of Pharmaceutical Industries and Associations, Wood, Cellulose, Tablet, Hydrolysis, Competition, Dairy, Growth, Food, Microcrystalline, Snack, Dietary supplement, Vegetable, Cosmetics, Federalisation of the European Union, Plant, Personal care, Fine chemical, Gum arabic

Global Microcrystalline Cellulose Market is anticipated to witness robust growth in the forecast period, 2024-2028.

Key Points: 
  • Global Microcrystalline Cellulose Market is anticipated to witness robust growth in the forecast period, 2024-2028.
  • The pharmaceutical industry is growing worldwide, with United States and China being the top 2 countries in the overall pharmaceutical market.
  • Microcrystalline cellulose is added to processed foods in the food and beverage industry to provide a creamy and smooth texture.
  • Additionally, the growing demand for processed food and shift towards ready-to-eat meals and bakery products is further anticipated to increase the demand for microcrystalline cellulose.

Senda Biosciences Appoints Luke O’Neill, Ph.D., as Chief Scientific Officer

Retrieved on: 
Jeudi, janvier 12, 2023
Research, Genetics, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, University, Az-Zubair Prize for Innovation and Scientific Excellence, Flagship Pioneering, Royal Society, Doctor of Philosophy, Royal Dublin Society, Pharmacology, United States Air Force Scientific Advisory Board, Royal, International Cytokine & Interferon Society, Trinity College Dublin, Inflammation, Trinity College, CSO, Biochemistry, Research, Receptor (biochemistry), Federalisation of the European Union, Macrophage, Immunology, Inflammasome, Management

Senda Biosciences , Inc., a company harnessing nature to enable the world’s first comprehensive programming of medicines, today announced the appointment of Luke O’Neill, Ph.D., as Chief Scientific Officer.

Key Points: 
  • Senda Biosciences , Inc., a company harnessing nature to enable the world’s first comprehensive programming of medicines, today announced the appointment of Luke O’Neill, Ph.D., as Chief Scientific Officer.
  • “Luke is a key addition to what is already a strong, effective leadership team,” said Guillaume Pfefer, Ph.D., Chief Executive Officer of Senda Biosciences and Partner at Flagship Pioneering.
  • “Luke is a world-renowned immunologist who has contributed so much to the organization in his corporate governance and scientific advisory roles.
  • He holds a Ph.D. in pharmacology from the University of London and conducted postdoctoral research at the University of Cambridge, UK.

Single Use Bioprocessing Global Market Report 2022: Surging Demand for Biopharmaceuticals Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Mercredi, décembre 28, 2022
Health, Biotechnology, Benchmark, Agriculture, Coronavirus, 3D, Geography, Water, EFPIA, Organization, Biotechnology, Federalisation of the European Union, Growth, Create, European Federation of Pharmaceutical Industries and Associations, Fine chemical, Marketing

The "Single Use Bioprocessing Global Market Report 2022: Ukraine-Russia War Impact" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Single Use Bioprocessing Global Market Report 2022: Ukraine-Russia War Impact" report has been added to ResearchAndMarkets.com's offering.
  • The regions covered in the single use bioprocessing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The surge in demand for biopharmaceuticals is expected to propel the growth of the single-use bioprocessing market going forward.
  • Therefore, the increasing demand for biopharmaceuticals is driving the growth of the single-use bioprocessing market.

IMIDomics Announces Appointment of Key Science and Medical Research Experts to Newly Formed Immunology Advisory Board

Retrieved on: 
Mercredi, décembre 7, 2022
Health, Infectious Diseases, General Health, Research, Science, Pharmaceutical, Biotechnology, Tao, Vall, Helen, Immune-mediated inflammatory diseases, Federalisation of the European Union, Ephraim, COVID-19, University of Barcelona, Natural killer T cell, Teaching hospital, Phosphorylation, Virus, Bristol Myers Squibb, Partnership, American Cancer Society, Inflammation, University, Hospital, University School, Machine learning, National academy, EFIS, MD, Signal transduction, Howard Hughes Medical Institute, Science, DNS, University of California, San Francisco, Faculty, Immunology, Homeostasis, Immune system, Microbiota, International Union of Immunological Societies, Patient, Immunotherapy, Research, Journal, Tyrosine, UCSF, IMID, Biomedical sciences, Long, DN Capital, Nicholas J. Pritzker, Pharmaceutical industry, Medical device, Biotechnology, Microbiology, Rheumatology

Members of the IMIDomics Immunology Advisory Board include:

Key Points: 
  • Members of the IMIDomics Immunology Advisory Board include:
    Andr Veillette, M.D.
  • Dr. Veillete is a member of the COVID-19 Vaccine Task Force and the Long COVID Task Force of the Government of Canada.
  • He serves on multiple academic and industry advisory boards and the Pfizer Board of Directors.
  • His research group studies Natural Killer cells, which recognize and eliminate cells that have become transformed or infected by viruses.

Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants

Retrieved on: 
Lundi, novembre 28, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Privacy, IMI, Clinical trial, ALM, Innovative Medicines Initiative, History, European Federation of Pharmaceutical Industries and Associations, University, Multimedia, Hospital, Clinical, Patient, Federalisation of the European Union, European Commission, European, Data, JU, EFPIA, Ethics, Facilitation, Research, Framework, Quality of life, Dream, Pharmaceutical industry, Almirall, EU

FACILITATE main objective is to help return the clinical trial data to the study participants, ready for reuse in either further research or in healthcare practice, improving the current situation where clinical data are isolated in separate repositories and cannot be used outside the clinical trial.

Key Points: 
  • FACILITATE main objective is to help return the clinical trial data to the study participants, ready for reuse in either further research or in healthcare practice, improving the current situation where clinical data are isolated in separate repositories and cannot be used outside the clinical trial.
  • In addition, the company also contributes with its expertise in the specification of clinical trial use cases, stakeholder requirements, and the development of end-user tools.
  • Facilitate is based on a patient-centred, data-driven technology platform with 27 partners from 17 EU and non-EU Member States.
  • At Almirall, we are excited to contribute to this patient-driven IMI project with our solid experience in clinical trials and our commitment to ethics and transparency.

Promote education on diabetes for a healthier tomorrow

Retrieved on: 
Lundi, novembre 14, 2022
Obesity, Education, Systematic review, European Food Safety Authority, Friends, International Diabetes Federation, Meta-analysis, Federalisation of the European Union, Raben Group, WDD, Social media, Health care, ISA, Diabetes, EFAD, Pleasure, Safety, Disease, Sugar, American Journal, IDF, Family, EFSA, Risk, Carbohydrate, Anton Greyling, Pharmaceutical industry, Soft drink

One in two people with diabetes dont know they have the disease and remain undiagnosed.

Key Points: 
  • One in two people with diabetes dont know they have the disease and remain undiagnosed.
  • Education on low/no calorie sweeteners can help people living with diabetes: ISA campaign for WDD 2022
    Both health professionals and people living with diabetes need to have better access to nutrition education in diabetes, including about the role of low/no calorie sweeteners in diabetes control.
  • Share the ISA campaign for World Diabetes Day 2022 on social media with your friends, family and network by using the dedicated hashtags #ISA4WDD, #WDD2022 and #EducationToProtect.
  • American Journal of Clinical Nutrition 2020; 112(4): 1002-1014
    EFSA Scientific opinion on the substantiation of health claims related to intense sweeteners.

Global Inflammatory Bowel Disease Drugs Market to Reach $34.5 Billion by 2031 at a 5.1% CAGR - ResearchAndMarkets.com

Retrieved on: 
Jeudi, novembre 24, 2022
Biotechnology, Pharmaceutical, Health, FDA, Prevalence, Inflammatory bowel disease, Hygiene, Ustekinumab, Ulcerative colitis, Federalisation of the European Union, Infliximab, Medical research, Pfizer, Adalimumab, Boehringer Ingelheim, Market share, Medscape, International Journal of Medical Sciences, Growth, Crohn's disease, Health, Distribution, Patient, Pharmaceutical industry

The global inflammatory bowel disease drugs market was valued at $20,988 million in 2021 and is projected to reach $34.513.56 million by 2031 registering a CAGR of 5.1% from 2022 to 2031.

Key Points: 
  • The global inflammatory bowel disease drugs market was valued at $20,988 million in 2021 and is projected to reach $34.513.56 million by 2031 registering a CAGR of 5.1% from 2022 to 2031.
  • ECCFA has collaborated with Medscape to conduct training session on biosimilars for the treatment of inflammatory bowel disease.
  • Moreover, development of pharmaceutical industries and improvement in healthcare spending are anticipated to drive the growth of the inflammatory bowel disease drugs market.
  • This has encouraged many key players to enter emerging market, thus offering lucrative growth opportunities in the inflammatory bowel disease drugs market.

Microcrystalline Cellulose Market Report 2022: New Grades of Microcrystalline Cellulose With Improved Pharmaceutical Characteristics Present Growth Opportunities - ResearchAndMarkets.com

Retrieved on: 
Vendredi, novembre 4, 2022
Other Manufacturing, Manufacturing, Asahi Kasei, Microcrystalline cellulose, Cellulose, Cosmetics, CAGR, Industry, Region, Population, Association, Hair, European Federation of Pharmaceutical Industries and Associations, Marketing, Food, Dairy, MCC, US, LCPC, Technology, SMCC, Federalisation of the European Union, Rayonier Advanced Materials, Renewable energy, Wood-plastic composite

Pure cellulose is available in market in various forms such as microcrystalline cellulose (MCC), powdered cellulose (PC), and low crystallinity powdered cellulose (LCPC).

Key Points: 
  • Pure cellulose is available in market in various forms such as microcrystalline cellulose (MCC), powdered cellulose (PC), and low crystallinity powdered cellulose (LCPC).
  • Development of new grades of microcrystalline cellulose with improved pharmaceutical characteristics including silicified microcrystalline cellulose (SMCC) and second generation MCC grades, is expected to increase its penetration in the pharmaceutical industry, and support market growth of microcrystalline cellulose.
  • Further, the wide applicability of microcrystalline cellulose is considered as another factor, driving growth of market.
  • North America held a dominant position in the global microcrystalline cellulose market in 2021, owing to growing pharmaceutical industry in the region.